<DOC>
	<DOCNO>NCT00250991</DOCNO>
	<brief_summary>The purpose study determine effect use combination two drug -- integrilin ( eptifibatide ) activase ( recombinant tissue plasminogen activator , rt-PA , recombinant t-PA ) -- dissolve blood clot patient stroke .</brief_summary>
	<brief_title>Combined Approach Lysis Utilizing Eptifibatide rt-PA Acute Ischemic Stroke ( CLEAR Stroke ) Trial</brief_title>
	<detailed_description>The Combined Approach Lysis Utilizing Eptifibatide rt-PA Acute Ischemic Stroke ( CLEAR Stroke ) trial part Specialized Program Translational Research Acute Stroke ( SPOTRIAS ) . The overall goal SPOTRIAS enhance delivery acute stroke patient care train acute stroke translational researcher . Stroke often occur blood flow brain stop block blood clot . When blood clot block blood supply brain , part brain may get enough blood oxygen survive . As result , permanent brain damage occur , affect person 's ability walk , talk , function independently . In order reduce risk permanent damage , important restore blood flow brain quickly possible . The CLEAR Stroke study enroll 100 participant acute stroke due blood clot . The purpose multi-center , randomize , double-blind study determine effect use combination two drug , integrilin ( eptifibatide ) activase ( recombinant tissue plasminogen activator , rt-PA , recombinant t-PA ) , dissolve blood clot . More specifically , CLEAR study do determine lower dose activase , give combination second drug , integrilin , safe treatment acute stroke . Activase , use alone , already approve Food Drug Administration ( FDA ) treatment patient stroke caused blockage artery brain give within 3 hour onset stroke symptom . Integrilin also already FDA-approved treatment blood clot cause heart attack . The investigational aspect study use integrilin stroke victim combination activase .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Patients must serious measurable neurological deficit NIH Stroke Scale due focal brain ischemia . An NIH Stroke Scale score &gt; 5 time intravenous study drug begin . Age : 18 80 year ( i.e . candidate must 18th birthday , 81st birthday ) . Intravenous therapy must initiate within 3 hour onset stroke symptom . History stroke past 3 month . Previous intracranial hemorrhage , neoplasm , subarachnoid hemorrhage , arterial venous malformation Clinical presentation suggest subarachnoid hemorrhage , even initial CT scan normal Hypertension time treatment ; systolic BP &gt; 185 diastolic &gt; 110 mmHg aggressive measure low blood pressure limit need . Presumed septic embolus Presumed pericarditis include pericarditis acute myocardial infarction Recent ( within 30 day ) surgery biopsy parenchymal organ Recent ( within 30 day ) trauma , internal injury ulcerative wound Recent ( within 90 day ) severe head trauma head trauma loss consciousness Any active recent ( within 30 day ) serious systemic hemorrhage Known hereditary acquire hemorrhagic diathesis , coagulation factor deficiency ; oral anticoagulant therapy prothrombin time great 15 INR &gt; 1.4 Baseline lab value : positive urine pregnancy test , glucose &lt; 50 &gt; 400 mg/dl , platelet &lt; 100,000 /mm3 , Hct &lt; 25 % , creatinine &gt; 4 mg/dl Ongoing renal dialysis , regardless creatinine If heparin administer within 48 hour , patient must normal partial thromboplastin time ( PTT ) Arterial puncture noncompressible site lumbar puncture previous 7 day Seizure onset stroke Preexisting neurological psychiatric disease would confound neurological functional evaluation Other serious , advanced , terminal illness condition investigator feel would pose significant hazard patient rtPA eptifibatide therapy initiated Patients whose peripheral venous access poor unable two standard peripheral Intravenous line start . Current participation another research drug treatment protocol . Patient start another experimental agent 90 day Informed consent obtain Any known history amyloid angiopathy . Exclusion Criteria/CT Scan : High density lesion consistent hemorrhage degree . Significant mass effect midline shift . Large ( 1/3 middle cerebral artery ) region clear hypodensity baseline CT scan . Sulcal effacement and/or loss greywhite differentiation alone contraindication treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>stroke</keyword>
	<keyword>integrilin</keyword>
	<keyword>eptifibatide</keyword>
	<keyword>activase</keyword>
	<keyword>recombinant tissue plasminogen activator</keyword>
	<keyword>rt-PA</keyword>
	<keyword>recombinant t-PA</keyword>
	<keyword>SPOTRIAS</keyword>
</DOC>